Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Conference Call February 21, 2024 5:00 PM ET
Company Participants
Pia Eaves - Vice President of Investor Relations
Terry Rosen - CEO
Jennifer Jarrett - COO
Dimitry Nuyten - CMO
Bob Goeltz - CFO
Juan Jaen - President
Conference Call Participants
Terence Flynn - Morgan Stanley
Peter Lawson - Barclays
Kaveri Pohlman - BTIG
Jonathan Miller - Evercore ISI
Yigal Nochomovitz - Citigroup
Robyn Karnauskas - Truist
Daina Graybosch - Leerink Partners
Operator
Hello and welcome to the Arcus Biosciences Full Year/Q4 2023 Earnings Call. My name is Elliot, and I’ll be coordinating your call today. [Operator Instructions].
I’d now like to hand over to Pia Eaves, Vice President of Investor Relations. The floor is yours. Please go ahead.
Pia Eaves
Hello, everyone and thank you for joining us on today’s conference call to discuss Arcus’s fourth quarter 2023 financial results and pipeline updates. I’d like to remind you that on this call, management will make forward-looking statements, including statements about our cash runway and our expected clinical development milestones and timelines.
All statements other than historical facts reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our annual report on Form 10-K, which has been filed with the SEC. We strongly encourage you to review our filings.
Today you’ll hear from our CEO, Terry Rosen; COO, Jennifer Jarrett; CMO, Dimitry Nuyten; and CFO, Bob Goeltz. We’ll also be joined by our President, Juan Jaen, for questions after the prepared remarks. During today’s call, we’ll refer to slides in our corporate deck, which can be found on the Investors section of our website.
With that, I’ll now turn it over to Terry.
Terry Rosen
Thanks very much, Pia, and thank you all for joining us today. We’ve really come a long way since our founding nine years ago, and I think it’s fair to say we have evolved into an integrated biopharmaceutical company. We’ve got seven molecules in clinical development, a broad late-stage portfolio, multiple mid-stage clinical trials, a robust discovery engine, and now something I think new, a line of sight to commercialization.
With $1.2 billion in cash and equivalents in runway into 2027, we’re well positioned to deliver on the promise of the late-stage pipeline that we’ve built. We start three new registrational trials. We’re going to continue to invest in our early-stage programs. We also have a partnership with Gilead, as well as collaborations with Taiho, Exelixis and AstraZeneca. And I think it’s very fair to say without these partnerships and the resources that these companies provide, we would not be able to execute on everything that we’re doing.